Global Vasomotor Symptoms Treatment Market Report and Forecast 2023-2031

Global Vasomotor Symptoms Treatment Market Report and Forecast 2023-2031

Global Vasomotor Symptoms Treatment Market Outlook

The global vasomotor symptoms treatment market size was valued at USD 8.8 billion in 2022 and is projected to grow at a CAGR of 6.70% during the forecast period of 2023-2031 to reach a value of USD 15.7 billion by 2031. The market growth can be attributed to the increasing prevalence of vasomotor symptoms, such as hot flashes and night sweats, associated with menopause and the rising awareness about women's health.

Global Vasomotor Symptoms Treatment Market: Introduction

Vasomotor symptoms treatment refers to medical interventions provided to women experiencing symptoms related to menopause, such as hot flashes, night sweats, and mood swings. The treatment options include hormone replacement therapy (HRT), non-hormonal therapies, and alternative treatments, such as herbal supplements and lifestyle changes. The increasing prevalence of vasomotor symptoms, coupled with an aging female population, is driving the demand for effective treatments. Other factors such as rising awareness about women's health, increasing government initiatives, and the growing demand for innovative treatment options are also expected to drive market growth.

Advancements in technology have also played a significant role in the growth of the vasomotor symptom’s treatment market. Telemedicine and online platforms have made it easier for women to access healthcare professionals and receive personalized advice on managing vasomotor symptoms. This has expanded the reach of vasomotor symptoms treatment and helped meet the growing demand for services.

Vasomotor Symptoms Epidemiology

Vasomotor symptoms affect approximately 75% of women during the menopausal transition and post menopause. These symptoms can significantly impact a woman's quality of life, leading to sleep disturbances, mood changes, and other health issues. The demand for vasomotor symptoms treatment is growing as more women seek help for menopausal symptoms.

Vasomotor Symptoms Treatment Market Segmentations

The market can be segmented based on route of administration, type of therapy, distribution channel, and region:

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Topical
Market Breakup by Therapy Type
  • Hormone Replacement Therapy (HRT)
  • Non-Hormonal Therapies
  • Alternative Treatments
Market Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Market Breakup by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others
Vasomotor Symptoms Treatment Market Scenario

The global vasomotor symptoms treatment market has experienced significant growth over the past few years, driven by factors such as the increasing prevalence of vasomotor symptoms, rising awareness about women's health, and the growing demand for innovative treatment options.

North America is currently the largest market for vasomotor symptoms treatment, accounting for a significant share of the global market. The region's large market share is driven by factors such as a high prevalence of vasomotor symptoms, a well-established healthcare infrastructure, and strong investment in women's health research and development in addition, the growing adoption of digital health technologies, such as telemedicine and online pharmacies, is further driving the growth of the market in North America. Europe is also a significant market for vasomotor symptoms treatment, with countries such as Germany and France leading the way. The region's market growth is driven by factors such as a large aging female population, increasing awareness of women's health issues, and government initiatives to address women's health concerns. Additionally, the region has a well-established healthcare system, which supports the delivery of vasomotor symptoms treatment.

Asia Pacific is another region that is experiencing significant growth in the vasomotor symptom’s treatment market. The region's market growth is driven by factors such as a large aging female population, increasing awareness of women's health concerns, and the growing adoption of digital health technologies. In addition, government initiatives to address women's health concerns are helping to drive the growth of the market in the region.

Key Players in the Global Vasomotor Symptoms Treatment Market

The report provides a detailed analysis of the key players involved in the vasomotor symptom’s treatment market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:
  • Bayer AG
  • Fervent Pharmaceuticals, LLC
  • Astellas Pharma Inc.
  • Frazier Healthcare Partners
  • Mitsubishi Tanabe Pharma Corporation
  • Eli Lilly and Company
  • AbbVie Inc.
  • AMAG Pharmaceuticals Inc.
  • Emcure Pharmaceuticals Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Vasomotor Symptoms Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Vasomotor Symptoms Treatment Market
8.1 Global Vasomotor Symptoms Treatment Market Overview
8.2 Global Vasomotor Symptoms Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Vasomotor Symptoms Treatment Market Historical Value (2015-2021)
8.2.1.2 Global Vasomotor Symptoms Treatment Market Forecast Value (2022-2030)
8.3 Global Vasomotor Symptoms Treatment Market by Route of Administration
8.3.1 Market Overview
8.3.1.1 Oral
8.3.1.2 Parenteral
8.3.1.2.1 Subcutaneous
8.3.1.2.2 Intravenous
8.3.1.3 Topical
8.4 Global Vasomotor Symptoms Treatment Market by Type of Therapy
8.4.1 Market Overview
8.4.1.1 Hormonal Therapies
8.4.1.1.1 Estrogen Replacement Therapies
8.4.1.1.2 Pregestational Therapies
8.4.1.2 Non-Hormonal Therapies
8.4.1.2.1 Clonidine
8.4.1.2.2 Serotonin Reuptake Inhibitors
8.4.1.2.3 Gabapentin
8.4.1.3 Others
8.5 Global Vasomotor Symptoms Treatment Market by Distribution Channel
8.5.1 Market Overview
8.5.1.1 Hospital Based Pharmacies
8.5.1.2 Online Pharmacies
8.5.1.3 Retail Pharmacies
8.6 Global Vasomotor Symptoms Treatment Market by Region
8.6.1 Market Overview
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Middle East and Africa
8.6.1.5 Latin America
9 North America Vasomotor Symptoms Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Vasomotor Symptoms Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Vasomotor Symptoms Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Vasomotor Symptoms Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Vasomotor Symptoms Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Vasomotor Symptoms Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Bayer AG
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Fervent Pharmaceuticals, LLC
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Astellas Pharma Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Frazier Healthcare Partners
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Mitsubishi Tanabe Pharma Corporation
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Eli Lilly and Company
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 AbbVie Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 AMAG Pharmaceuticals Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Emcure Pharmaceuticals Limited
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Merck & Co., Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Novartis AG
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 Novo Nordisk A/S
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
15.13 Pfizer Inc.
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.13.5 Certifications
15.14 Teva Pharmaceutical Industries Ltd.
15.14.1 Company Overview
15.14.2 Product Portfolio
15.14.3 Demographic Reach and Achievements
15.14.4 Mergers and Acquisitions
15.14.5 Certifications
16 Global Vasomotor Symptoms Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings